PF-07994525 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment, PF-07994525, for individuals with relapsed or refractory multiple myeloma (R/R MM). The goal is to determine the treatment's safety and effectiveness in combating cancer. Initially, the study will identify the appropriate dose, then expand to include more participants for additional data. Suitable candidates have had multiple myeloma for some time and have tried at least three other treatments without success. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that PF-07994525 is likely to be safe for humans?
Research shows that PF-07994525 remains in the early stages of testing to determine its safety and effectiveness for treating cancer. As a Phase 1 trial, it marks one of the first instances of testing in humans. Phase 1 trials primarily assess how well participants tolerate the treatment and identify any side effects.
Currently, detailed safety information is limited because the treatment is still under investigation. This phase focuses on identifying the safest dose for future trials. It's important to understand that early trials like this can involve some risks, as researchers continue to learn about the treatment's effects on the human body. Researchers closely monitor participants to manage any possible side effects.12345Why do researchers think this study treatment might be promising?
PF-07994525 is unique because it offers a new approach to treating cancer by focusing on monotherapy dose escalation and expansion. Unlike traditional treatments like chemotherapy and radiation, which often target all rapidly dividing cells, PF-07994525 is designed to specifically target cancer cells, potentially reducing damage to healthy cells. Researchers are excited about this treatment because it may provide a more precise attack on cancer cells, which could lead to fewer side effects and improved outcomes for patients.
What evidence suggests that PF-07994525 might be an effective treatment for R/R MM?
PF-07994525 is an experimental drug under development for advanced cancers, including multiple myeloma. The trial consists of two parts: Part 1 focuses on monotherapy dose escalation, and Part 2 on monotherapy dose expansion. The drug is taken orally, offering convenience. It targets cancer cells directly. Early findings suggest it might shrink tumors or slow their growth. Researchers are investigating the drug's safety and efficacy, with some early evidence indicating potential effectiveness in treating cancer.12567
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for adults with advanced multiple myeloma who have tried at least three previous treatments that didn't work or caused bad side effects. Participants must be in good physical condition and meet certain lab test requirements related to their cancer.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
PF-07994525 dose escalation to assess safety, tolerability, and preliminary antitumor activity in participants with R/R MM
Dose Expansion
PF-07994525 evaluated in additional participants to further assess safety, PK, PD, and preliminary anti-tumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PF-07994525
Trial Overview
The study tests a new drug, PF-07994525, given alone in different doses to find the safest amount and see how well it works against advanced multiple myeloma. Midazolam may also be used to help understand how the body processes PF-07994525.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Monotherapy Dose Escalation
Monotherapy Dose Expansion
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Citations
An Open-Label Study to Evaluate PF-07994525 in ...
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), ...
An Open-Label Study to Evaluate PF-07994525 in ...
Part 1: Recommended Monotherapy Dose for Expansion (RDE), RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings ...
An Open-Label Study to Evaluate PF-07994525 in ... - GoodDay
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), ...
4.
theglobeandmail.com
theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/740050/pfizer-advances-early-stage-cancer-candidate-pf-07994525-extending-its-oncology-pipeline/Pfizer Advances Early-Stage Cancer Candidate PF ...
The main treatment is PF-07994525, an oral experimental cancer drug given as a single-agent therapy. Midazolam, another oral drug, is used in a ...
PF 07994525 - AdisInsight
PF 07994525, an orally administered candidate is being developed by Pfizer for the treatment of advanced cancer including multiple myeloma.
Pfizer Reports Positive Mid-Stage Breast Cancer Trial ...
The research showed that progression-free survival was much better than usual therapy.The trial included 264 people who had already been treated ...
7.
trial.medpath.com
trial.medpath.com/clinical-trial/67ea8fba2c3f9fb2/nct07518329-ala-101-car-inkt-cells-cd19-non-hodgkin-lymphoma-leukemiaStudy of ALA-101 in Patients With CD19 Positive Non ...
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers. Not Yet RecruitingPhase 1. Pfizer. Posted 2/22/2026. Updated ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.